PMC8107674_01
Changes in tumor measurement from baseline in patient 001, who underwent treatment with PARP inhibitor on the basis of ctDNA analysis showing BRCA2 R3052W mutation. (a) Scatter plot illustrates changes in lesion tumor burden. Computed tomography (CT) scan data at the most recent time prior to cycle 1, day 1 is chosen as baseline (time 0). The horizontal (x) axis shows time at restaging CT scans as months from baseline. The vertical (y) axis shows percentage of change in tumor measurement from baseline. Each dot represents a data point collected at each restaging CT scan. The blue line represents PR (>=30% decrease in tumor measurements from baseline, based on RECIST 1.1). (b) Scatter plot illustrates changes in tumor marker levels over time. (c) Representative CT images from the patient at baseline. (d) Representative CT images from the patient after 20.6 months of targeted therapy with PARP inhibitor.. Red arrows indicate target lesions.
10.1177_17588359211001538-fig1.jpg
PMC8107674_01_10.1177_17588359211001538-fig1.jpg
fig1-17588359211001538
Thus far, she has received 21 cycles of the PARP inhibitor, and her best RECIST response was PR (76% decrease from baseline per RECIST 1.1) (Figure 1).
PMC8107674_02
Changes in tumor measurement from baseline in patient 002, who underwent treatment with MEK/RAF pathway inhibitor on the basis of ctDNA analysis showing RAF1 amplification. (a) Representative computed tomography (CT) images from the patient at baseline. (b) Representative CT images from the patient after 6.8 months of treatment with MEK/RAF pathway inhibitor.. Red arrows indicate target lesions.
10.1177_17588359211001538-fig2.jpg
PMC8107674_03_10.1177_17588359211001538-fig2.jpg
fig2-17588359211001538
Her best RECIST response was SD with a 14% decrease in tumor measurement from baseline per RECIST 1.1, and the PFS duration was 9.1 months (Figure 3 and Table 2).
PMC8107674_03
Changes in tumor measurement from baseline in patient 002, who underwent treatment with MEK/RAF pathway inhibitor on the basis of ctDNA analysis showing RAF1 amplification. (a) Representative computed tomography (CT) images from the patient at baseline. (b) Representative CT images from the patient after 6.8 months of treatment with MEK/RAF pathway inhibitor.. Red arrows indicate target lesions.
10.1177_17588359211001538-fig2.jpg
PMC8107674_03_10.1177_17588359211001538-fig2.jpg
fig2-17588359211001538
Her best RECIST response was SD with a 14% decrease in tumor measurement from baseline per RECIST 1.1, and the PFS duration was 9.1 months (Figure 3 and Table 2).
Changes in tumor measurement from baseline in patient 003, who underwent treatment with PARP inhibitor on the basis of ctDNA analysis showing BRCA1 Q356* mutation. (a) Representative computed tomography (CT) images from the patient at baseline. (b) Representative CT images from the patient after 6.5 months of treatment with PARP inhibitor. (c) Representative positron emission tomography (PET) overview image from the patient at baseline. (d) Representative PET overview image from the patient after 6.5 months of treatment with PARP inhibitor.. Red arrows indicate target lesions.
10.1177_17588359211001538-fig3.jpg
PMC8107674_03_10.1177_17588359211001538-fig3.jpg
fig3-17588359211001538
Her best RECIST response was SD with a 14% decrease in tumor measurement from baseline per RECIST 1.1, and the PFS duration was 9.1 months (Figure 3 and Table 2).